/

MREO

Mereo BioPharma Group plcClosed

0.3200+0.00 +1.52%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.3250 +1.56%

Open

0.3112

Prev close

0.3152

Day range

0.29740.3210

52-week range

0.20002.37

Volume

1.26M0.31×

Mkt cap

51.10M

P/E ttm

—

Fwd P/E

-13.98

EPS ttm

-0.2000

Div yield

0.00%

Earnings

Aug 11, 2026

From 52w high

−86.50%

Price Chart

Yahoo Finance · delayed

MREOOct 13, 2026O 0.3110H 0.3210L 0.2970C 0.3200+0.0050 (+1.59%)Vol 1.26M

SMA 500.3081
SMA 2000.3541

1Y change −84.00% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MREO Mereo BioPharma Group plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.57%
1 month: +14.29%
3 months: +1.91%
6 months: −2.74%
Year to date: −23.26%
1 year: −84.00%

Valuation & ownership

Market cap: 51.10M
Enterprise value: 22.01M
P/E (ttm): —
Forward P/E: -13.98
PEG ratio: —
Price / book: 1.78
Price / sales (ttm): —
EV / EBITDA: -0.68
EPS (ttm): -0.2000
EPS (forward): -0.0229
Beta (5y monthly): 0.14
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 159.69M
Float: 125.02M
Short % of float: 2.06%
Short ratio (days): 1.42
Held by insiders: 0.75%
Held by institutions: 35.47%
Avg volume (3m): 4.10M
50-day average: 0.3080
200-day average: 0.3640
52-week change: −84.00%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 47.1
vs 50-day SMA: +3.87%
vs 200-day SMA: −9.63%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.55%
Realised vol (20d, ann.): 104.6%
From 52-week high: −86.50%
From 52-week low: +60.00%

ANR

Analyst Consensus

5 analysts

Consensus

Buy

2.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

1.97

+516.68% implied

Low 0.9822Median 1.95High 3.01

Recommendation trend

Now5 / 2 / 1
1m ago / 2 /

DES

About Mereo BioPharma Group plc

Yahoo Finance profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Sector: Healthcare
Industry: Biotechnology
Employees: 39
Headquarters: London, United Kingdom
Website: mereobiopharma.com
Officers: Dr. Denise Vera Scots-Knight Ph.D.

SEAS

Seasonality · MREO

2019–2026 · monthly returns

Strongest month Jun +40.01%Weakest month Mar −17.78%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	5.5	-15.7	-11.1	-18.8	28.4	-7.6	7.9	-22.2	50.6	-20.4			−23.3%
2025	-14.0	-20.3	-6.3	15.1	-17.0	26.0	-37.6	1.2	20.5	-7.8	-1.6	-77.7	−88.1%
2024	64.1	0.3	-13.2	-7.6	13.1	4.3	12.8	15.5	-12.4	2.4	-14.4	-2.9	+51.5%
2023	24.7	-4.6	-20.7	85.3	-22.9	30.7	0.8	3.0	-5.8	55.4	4.2	10.5	+208.0%
2022	-18.1	-5.3	-9.7	-44.6	-18.5	121.8	8.0	-0.8	-28.3	16.1	-21.2	-4.8	−53.1%
2021	-24.0	43.0	-13.4	5.3	-7.9	-3.1	-18.9	8.6	-13.3	-7.0	-21.8	-9.1	−55.3%
2020	-48.7	10.0	-43.5	31.1	-7.3	140.9	-6.9	4.9	-12.4	-9.5	3.0	46.7	+9.1%
2019					-24.1	-40.7	3.2	41.2	-18.8	-1.5	-19.3	38.4	−41.4%

13F

Investors Holding MREO

latest 13F filings of 29 followed managers

Investors holding MREO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$16.6K	0.00%	52.10K	+7.6%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

MREO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MREO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Mereo BioPharma Group plc

Seasonality · MREO

Insider Activity · MREO

Congress Trades · MREO

Investors Holding MREO

Investors Holding MREO

Congress Trades · MREO

Insider Activity · MREO

Seasonality · MREO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Mereo BioPharma Group plc

Financial Snapshot

Earnings & Dividends

News